SESSION 5: Oral Abstracts

Lead Author(s)

• 

  Pooja Ghatalia, MD

  Fox Chase Cancer Center
  Philadelphia, PA, United States

  Disclosure(s): Funding to my institution: Merck (Ongoing); Oryzon (Ongoing)
  Research Grant to my institution: Bristol Myers Squibb (Ongoing)

  Slides
• 

  Kate Glennon, BSc

  McGill University, Montreal, Canada
  McGill University
  Montreal, QC, Canada

  Disclosure(s): No financial relationships to disclose

  Slides
• 

  Shinji Ohtake, MD

  University of California, Los Angeles
  University of California, Los Angeles
  Los Angeles, CA, United States

  Disclosure(s): No financial relationships to disclose

  Slides
• 

  Sumanta Pal, MD

  City of Hope Comprehensive Cancer Center, Duarte, CA, USA
  Duarte, CA, United States

  Disclosure(s): Travel support: CRISPR Therapeutics (Ongoing); Ipsen (Ongoing)

  Slides

Presentations:

• 2:35 PM – 2:45 PM CST

  Zanzalintinib (XL092) in clear cell renal cell carcinoma (ccRCC): Results from STELLAR-001
  

  Lead Author: Sumanta Kumar Pal, MD – City of Hope Comprehensive Cancer Center, Duarte, CA, USA
• 2:45 PM – 2:55 PM CST

  Development of models of Neurofibromatosis 2 (NF2) loss in kidney cancer of Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC)
  

  Lead Author: Shinji Ohtake, MD – University of California, Los Angeles
• 2:55 PM – 3:05 PM CST

  Germline susceptibility to renal cell carcinoma and implications for genetic screening
  

  Lead Author: Kate I. Glennon, BSc – McGill University, Montreal, Canada
• 3:05 PM – 3:15 PM CST

  LITESPARK-013: Randomized Phase 2 Study of Two Doses of Belzutifan in Patients With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
  

  Lead Author: Pooja Ghatalia, MD – Fox Chase Cancer Center